Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone During Combined Treatment With Paroxetine
- 1 June 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 23 (3) , 223-227
- https://doi.org/10.1097/00007691-200106000-00007
Abstract
The effects of paroxetine on steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) were studied in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized using risperidone therapy (4–8 mg/d) also received paroxetine (20 mg/d) for 4 weeks. During paroxetine administration, mean plasma concentrations of risperidone increased significantly (PKeywords
This publication has 29 references indexed in Scilit:
- Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.Psychopharmacology, 2001
- Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidonePsychopharmacology, 1999
- (S)-ketoprofen accumulation in premature neonates with renal failure who were exposed to the racemate during pregnancyPublished by Wiley ,1999
- Therapeutic Drug Monitoring of Risperidone Using a New, Rapid HPLC Method: Reappraisal of Interindividual Variability FactorsTherapeutic Drug Monitoring, 1999
- Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1999
- Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone TherapyTherapeutic Drug Monitoring, 1998
- ParoxetineDrugs, 1998
- Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of SchizophreniaCNS Drugs, 1996
- Survey on the pharmacodynamics of the new antipsychotic risperidonePsychopharmacology, 1994
- Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjectsClinical Pharmacology & Therapeutics, 1993